AZD4573

SKU: orb1710347

Description

AZD4573 is a potent and selective CDK9 inhibitor with an IC50 below 4 nM, designed for transient target engagement. It is utilized in hematologic malignancy research, demonstrating activity in both in vitro assays and in vivo xenograft models for cancers like acute myeloid leukemia.

Research Area

Cell Biology

Key Properties

• CAS Number: 2057509-72-3
• MW: 429.94
• Purity: 99.63% (May vary between batches)
• Formula: C₂₂H₂₈ClN₅O₂
• SMILES: CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1
• Target: CDK
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (9.3 mM);DMSO:118.75 mg/mL (276.2 mM)

Bioactivity

• Target IC50:
  CDK9:4 nM (IC50)
• In Vivo:
  AZD4573 demonstrates a short half-life (<1 hour) in multiple species (dog, rat, monkey) and possesses good solubility for intravenous administration.
• In Vitro:
  Short-term administration of AZD4573 induced a swift, dose- and time-dependent reduction in cellular pSer2-RNAPII levels, which in turn activated caspase 3, leading to apoptosis across a wide spectrum of hematological cancer cell lines. Notably, caspase activation exhibited an EC50 of 13.7 nM in the acute myeloid leukemia model MV4-11.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

AZD-4573, AZD4573, AZD 4573, CDK9, CDK, Cyclin dependent kinase, Inhibitor, inhibit

Compound Identifiers

PubChem CID

124155204